サインイン 無料でサインアップします。

Neuland Laboratoriesの推定成長EPS Q/Q

Neuland Laboratoriesの推定成長EPS Q/Qは何ですか。

Neuland Laboratories Limitedの推定成長EPS Q/Qは66.02%です。

推定成長EPS Q/Qの定義は何ですか。



期待される四半期ごとのEPS成長率は、過去四半期の業績と比較して、次の四半期の企業EPSの推定増加です。

The prospective EPS growth rate is a predicted estimate of the earnings per share growth rate towards the current quarter and expressed as a percentage compared to the respective past quarter. The estimated earnings per share growth rate is an important factor for judging a company's value. Comparing EPS history with stock price history helps determine the most likely future direction of the stock price.

Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.

BSEのセクタHealth Careにおける推定成長EPS Q/Qの企業と比べるNeuland Laboratories

Neuland Laboratoriesは何をしますか。

Neuland Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. The company's APIs are used in various therapeutic areas, including antiasthmatics, cardiovasculars, antifungal, anticonvulsants, antiemetic, central nervous system, fluoroquinolones, corticosteroids, antipsychotic, antibacterial and anti-parkinson, anti-ulcerants, and prostaglandins. It also provides custom manufacturing solutions, as well as peptide synthesis services. The company was founded in 1984 and is headquartered in Hyderabad, India.

Neuland Laboratoriesと類似の推定成長eps q/q